3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Turcot syndrome
1
Stomach Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
5
Nivolumab
5
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
sintilimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
danvatirsen
1
camrelizumab
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Immunoglobulin G
1
IMM-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
DEAE-Dextran
×
Gastrointestinal
×
Clear all
NCT07403877
2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2
Not yet recruiting
114 enrolled